FrancophonIA/ELRC3.0 huggingface dataset:
English: • damage to the tiny filters inside your kidneys (glomerulonephritis).
Maltese:  ħsara lill-filtri ċkejkna ġewwa kliewi tiegħek (glomerulonefrite).
English: Common side effects (may affect up to 1 in 10 people):
Maltese: Effetti sekondarji komuni (jista' jaffetwa sa pazjent wieħed minn kull 10 persuni):
English: Treatment with pegfilgrastim alone does not preclude thrombocytopenia and anaemia because full dose myelosuppressive chemotherapy is maintained on the prescribed schedule.
Maltese: Tromboċitopenja u anemija Kura b'pegfilgrastim waħdu ma jeskludix tromboċitopenija u anemija minħabba li tinżamm id-doża sħiħa ta' kimoterapija majelosoppressiva fl-iskeda preskritta.
English: • if you experience an allergic reaction including weakness, drop in blood pressure, difficulty breathing, swelling of the face (anaphylaxis), redness and flushing, skin rash and areas of the skin that itch
Maltese: Reazzjonijiet ta' sensittività eċċessiva, inkluż raxx tal-ġilda, urtikarja, anġjoedema, qtugħ ta' nifs,
English: Do not use the pre-filled syringe if:
Maltese: Sustanza mhux attiva li għandha azzjoni magħrufa:
English: The pharmacokinetics of pegfilgrastim were studied in 37 paediatric patients with sarcoma, who received 100 μg/kg pegfilgrastim after the completion of VAdriaC/IE chemotherapy.
Maltese: Il-farmakokinetika ta' pegfilgrastim kienet studjata f'37 pazjent pedjatriku b'sarkoma, li rċevew
English: How to store Pelmeg
Maltese: X'fih Pelmeg
English: Do not administer Pelmeg to patients with a history of hypersensitivity to pegfilgrastim or filgrastim.
Maltese: M'hemmx dejta jew hemm dejta limitata dwar l-użu ta' pegfilgrastim f'nisa.
English: The full EPAR and risk management plan summary for Evotaz can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Maltese: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: This was comparable to a reduction in 87% of patients (304 of 348) treated with atazanavir and ritonavir.
Maltese: Dan kien komparabbli ma' tnaqqis f'87% tal-pazjenti (304 minn 348) ikkurati bl-atażanavir u ritonavir.
English: Other information about Evotaz
Maltese: Informazzjoni oħra dwar Evotaz
English: This is a summary of the European public assessment report (EPAR) for Evotaz.
Maltese: Dan huwa sommarju tar-rapport pubbliku Ewropew ta' valutazzjoni (EPAR) għal Evotaz.
English: Evotaz is available as tablets that contain 300 mg of atazanavir and 150 mg of cobicistat.
Maltese: Evotaz jiġi bħala pilloli li fihom 300 mg ta' atażanavir u 150 mg ta' kobiċistat.
English: Why is Evotaz approved?
Maltese: Għaliex ġie approvat Evotaz?
English: Evotaz is an antiviral medicine used in combination with other medicines to treat adults infected with human immunodeficiency virus type 1 (HIV-1), a virus that causes acquired immune deficiency syndrome (AIDS).
Maltese: Evotaz huwa mediċina antivirali li tintuża f'kombinazzjoni ma' mediċini oħra fil-kura ta' pazjenti infettati bil-virus tal-immunodefiċjenza umana tat-tip 1 (HIV-1), virus li jikkawża s-sindromu talimmunodefiċjenza akkwiżita (AIDS).
English: Overall, 85% of patients (293 out of 344) treated with atazanavir and cobicistat achieved this reduction.
Maltese: B'mod ġenerali, 85% tal-pazjenti (293 minn 344) ikkurati bl-atażanavir u l-kobiċistat kisbu dan it-tnaqqis.
English: Atazanavir is a protease inhibitor.
Maltese: L-atażanavir hija inibitur tal-proteażi.
English: The main measure of effectiveness was the proportion of patients in whom the HIV-1 count in the blood (known as viral load) was reduced to less than 50 copies/ml after 48 weeks of treatment.
Maltese: Ilkejl ewlieni tal-effikaċja kien il-proporzjon ta' pazjenti li l-għadd tal-HIV-1 fid-demm tagħhom (magħrufa bħala tagħbija virali) tnaqqas għal inqas minn 50 kopja/ml wara 48 ġimgħa ta' kura.
English: What are the risks associated with Evotaz?
Maltese: X'inhuma r-riskji assoċjati ma' Evotaz?
English: The active substances in Evotaz are already available in the EU as individual medicines: atazanavir is available as Reyataz and cobicistat as Tybost.
Maltese: Is-sustanzi attivi f'Evotaz huma diġà disponibbli fl-UE bħala mediċini individwali: l-atażanavir huwa disponibbli bħala Reyataz u l-kobiċistat bħala Tybost.
English: Atazanavir and cobicistat were compared with atazanavir and ritonavir; all patients also received the HIV medicines emtricitabine and tenofovir disoproxil.
Maltese: L-atażanavir u l-kobiċistat tqabblu mal-atażanavir u ritonavir; il-pazjenti kollha rċevew ukoll il-mediċini kontra l-HIV emtricitabine u tenefovir disoproxil.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Evotaz on 13 July 2015.
Maltese: Il-Kummissjoni Ewropea tat awtorizzazzjoni għat-tqegħid fis-suq valida fl-Unjoni Ewropea kollha għal Evotaz fit-13 ta' Lulju 2015.
English: Evotaz atazanavir / cobicistat
Maltese: Evotaz atażanavir / kobiċistat
English: It blocks an HIV enzyme called protease from working.
Maltese: Din timblokka enzżma tal-HIV imsejħa proteażi milli taħdem.
English: Because atazanavir and cobicistat have both previously been shown to be effective and are authorised for use in the treatment of HIV infection, studies were mainly carried out to show that Evotaz produced similar levels of atazanavir in the blood to the two active substances given separately, and to atazanavir given with a different booster medicine, ritonavir (an established combination).
Maltese: Minħabba li l-atażanavir u l-kobiċistat it-tnejn li huma diġà ntwerew li huma effikaċi u huma awtorizzati għall-użu fil-kura tal-infezzjoni tal-HIV, l-istudji prinċipalment twettqu biex jintwera li Evotaz ipproduċa livelli simili tal-atażanavir fid-demm għaż-żewġ sustanzi attivi meta jingħataw b'mod separat, u għallatażanavir meta jingħata ma' mediċina buster differenti, ritonavir (kombinazzjoni stabbilita).
English: Evotaz contains the active substances atazanavir and cobicistat.
Maltese: Evotaz fih is-sustanzi attivi atażanavir u kobiċistat.
English: Evotaz's adverse effects were similar to those that occur with the individual medicines.
Maltese: L-effetti avversi ta' Evotaz kienu simili għal dawk li jseħħu fil-mediċini individwali.
English: How does Evotaz work?
Maltese: Kif jintuża Evotaz?
English: Evotaz, taken with other HIV medicines, reduces HIV in the blood and keeps the virus at a low level.
Maltese: Evotaz, meħud flimkien ma' mediċini oħrajn kontra l-HIV, inaqqas l-HIV fid-demm u jżomm il-virus f'livell baxx.
English: In addition, the use of atazanavir with cobicistat has been evaluated in one main study in 698 HIV patients who had not been treated previously.
Maltese: Barra minn hekk, l-użu tal-atażanavir mal-kobiċistat ġie evalwat fi studju prinċipali wieħed f'698 pazjent b'HIV li ma ġewx ikkurati qabel.
English: A risk management plan has been developed to ensure that Evotaz is used as safely as possible.
Maltese: Ġie żviluppat pjan ta' ġestjoni tar-riskju biex jiġi żgurat li Evotaz jintuża bl-aktar mod sigur possibbli.
English: Both active substances have already been shown to be effective and Evotaz may be a useful substitute for atazanavir accompanied by ritonavir as a booster.
Maltese: Iż-żewġ sustanzi attivi diġà ntwerew li huma effikaċi u Evotaz jista' jkun sostitut utli għall-atażanavir flimkien ma' ritonavir bħala buster.
English: 1 ml (150 mg/ml) 6 (3 x 2) pre-filled syringes (multipack)
Maltese: 1 ml (150 mg/ml) 6 (3 x 2) siringi mimlija għal-lest (pakkett multiplu)
English: 1 ml (150 mg/ml) 6 (3 x 2) pre-filled pens (multipack)
Maltese: 1 ml (150 mg/ml) 6 (3 x 2) pinen mimlija għal-lest (pakkett multiplu)
English: 1 ml (150 mg/ml) 2 pre-filled syringes
Maltese: 1 ml (150 mg/ml) 2 siringi mimlija għal-lest
English: 1 ml (150 mg/ml) 2 pre-filled pens
Maltese: 1 ml (150 mg/ml) 2 pinen mimlija għal-lest
English: EMA/235/2016 EMEA/H/C/003825
Maltese: EMA/235/2016 EMA/H/C/003825
English: The full EPAR and risk management plan summary for Kovaltry can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Maltese: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: Other information about Kovaltry
Maltese: Informazzjoni oħra dwar Kovaltry
English: If they occur they may include: angioedema (swelling of tissues under the skin), burning and stinging at the injection site, chills, flushing, itchy rash over the whole body, headache, hives, hypotension (low blood pressure), lethargy, nausea (feeling sick), restlessness, tachycardia (rapid heartbeat), tightness of the chest, tingling, vomiting and wheezing.
Maltese: Jekk jiġu esperjenzati dawn jinkludu: anġjodema (nefħa fit-tessuti ta' taħt il-ġilda), ħruq u tingiż fis-sit tal-injezzjoni, tertir, fwawar, raxx bil-ħakk fuq il-ġisem kollu, uġigħ ta' ras, ħorriqija, ipotensjoni (pressjoni tad-demm baxxa), ħedla, nawżja (tħossok ma tiflaħx), nuqqas ta' sabar, takikardja (taħbit tal-qalb mgħaġġel), għafis tas-sider, tnemnim, rimettar u tħarħir ta' nifs.
English: This is a summary of the European public assessment report (EPAR) for Kovaltry.
Maltese: Dan huwa sommarju tar-rapport pubbliku Ewropew ta' valutazzjoni (EPAR) għal Kovaltry.
English: Why is Kovaltry approved?
Maltese: Għaliex ġiet approvat Kovaltry?
English: It contains the active substance octocog alfa, which is the same as human factor VIII.
Maltese: Fih is-sustanza attiva octocog alfa, li hija l-istess bħall-fattur VIII uman.
English: What are the risks associated with Kovaltry?
Maltese: X'inhuma r-riskji assoċjati ma' Kovaltry?
English: The effectiveness of Kovaltry in preventing and treating bleeding has been shown in a main study involving 62 patients aged 12 years or older with severe haemophilia A who were previously treated with other factor VIII products.
Maltese: L-effikaċja ta' Kovaltry fil-prevenzjoni u l-kura ta' fsada ntweriet fi studju ewlieni li involva 62 pazjent li għandhom 12-il sena jew iktar b'emofilja A severa li kienu kkurati qabel bi prodotti oħrajn talfattur VIII.
English: The active substance in Kovaltry, octocog alfa, works in the body in the same way as human factor VIII.
Maltese: Is-sustanza attiva f'Kovaltry, octocog alfa, taħdem fil-ġisem bl-istess mod bħall-fattur VIII uman.
English: About 70% of the bleeding events that occurred were managed with a single injection of Kovaltry, and about another 15% responded to a second injection; the response was considered good or excellent in around 80% of cases.
Maltese: Madwar 70 % tal-avvenimenti ta' fsada li seħħew kienu mmaniġġjati b'injezzjoni waħda ta' Kovaltry, u madwar 15 % oħra rrispondew għal injezzjoni oħra; ir-rispons kien ikkunsidrat bħala tajjeb jew eċċellenti f'madwar 80 % tal-każijiet.
English: A risk management plan has been developed to ensure that Kovaltry is used as safely as possible.
Maltese: Ġie żviluppat pjan ta' ġestjoni tar-riskju biex jiġi żgurat li Kovaltry jintuża bl-aktar mod sigur possibbli.
English: There is also a risk with factor VIII medicines that some patients will develop inhibitors (antibodies) against factor VIII, causing the medicine to stop working and resulting in a loss of bleeding control.
Maltese: Hemm ukoll riskju li bil-mediċini ta' fattur VIII ċerti pazjenti jiżviluppaw inibituri (antikorpi) kontra fattur VIII, fejn il-mediċina tieqaf tkun effikaċi u dan jirriżulta f'telf tal-kontroll tal-fsada.
English: For the full list of all side effects and restrictions with Kovaltry, see the package leaflet.
Maltese: Għal-lista sħiħa tal-effetti sekondarji u restrizzjonijiet b'Kovaltry, ara l-fuljett ta' tagħrif.
English: Data from a supportive study also confirmed the benefits of preventative treatment with Kovaltry in reducing the number of bleeds.
Maltese: Id-data minn studju ta' appoġġ ikkonfermat ukoll il-benefiċċji tal-kura preventiva b'Kovaltry biex jitnaqqas in-numru ta' fsadat.
English: Kovaltry is available as a powder and solvent used to make a solution for injection.
Maltese: Kovaltry jiġi bħala trab u solvent li jintuża biex tiġi prodotta soluzzjoni għall-injezzjoni.
English: Hypersensitivity (allergic) reactions are uncommon with Kovaltry, affecting from 1 patient in 1,000 to less than 1 patient in 100.
Maltese: Reazzjonijiet (allerġiċi) ta' sensittività eċċessiva mhumiex komuni b'Kovaltry, hekk kif jaffettwaw minn pazjent wieħed minn kull 1,000 sa inqas minn pazjent wieħed minn kull 100.
English: Kovaltry is a medicine used for the treatment and prevention of bleeding in patients with haemophilia A (an inherited bleeding disorder caused by lack of a clotting protein called factor VIII).
Maltese: Kovaltry jintuża għall-kura u l-prevenzjoni ta' fsada f'pazjenti li jbatu mill-emofilja A (marda li tintiret u tikkawża t-telf tad-demm ikkaġunata minn nuqqas ta' proteina li tgħaqqad id-demm li tissejjaħ fattur VIII).
English: A second study involved 51 children under 12 years of age previously treated with other factor VIII products, who also had 3.8 bleeds per year on average during treatment with Kovaltry (mostly related to injuries).
Maltese: Studju ieħor involva 51 tifel u tifla li għandhom anqas minn 12-il sena li ġew ikkurati qabel bi prodotti oħra tal-fattur VIII, li kellhom ukoll 3.8 fsadat fis-sena bħala medja matul il-kura b'Kovaltry (fil-biċċa lkbira relatati ma' ġrieħi).
English: Patients with haemophilia A lack factor VIII, a protein needed for normal clotting of the blood, and as a result, they bleed readily and may have problems such as bleeding into the joints, muscles and internal organs.
Maltese: Pazjenti b'emofilja A m'għandhomx fattur VIII, proteina meħtieġa għal koagulazzjoni normali taddemm, u dan iwassal biex ikollhom fsada mill-ewwel u jista' jkollhom problemi bħal fsada fil-ġogi, il
English: This compared with an average of 6.9 bleeds per year before Kovaltry treatment.
Maltese: Dan meta mqabbel ma' medja ta' 6.9 fsadat fis-sena qabel il-kura b'Kovaltry.
English: In addition, the company that markets Kovaltry will complete studies to investigate the safety and efficacy of the medicine in patients who have not previously been treated with other factor VIII products, and to provide further evidence of the safety and efficacy of long-term treatment with Kovaltry in children.
Maltese: Barra minn hekk, il-kumpanija li tqiegħed Kovaltry fis-suq sejra tlesti studji biex tinvestiga s-sigurtà u l-effikaċja tal-mediċini f'pazjenti li ma ġewx ikkurati qabel bi prodotti oħra tal-fattur VIII, u biex tipprovdi iktar evidenza dwar is-sigurtà u l-effikaċja ta' kura fit-tul b'Kovaltry fit-tfal.
English: What measures are being taken to ensure the safe and effective use of Kovaltry?
Maltese: X'miżuri qegħdin jittieħdu biex jiġi żgurat l-użu sigur u effettiv ta' Kovaltry?
English: Further information on Tyverb can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Maltese: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: Tyverb was originally given ‘conditional approval'.
Maltese: Tyverb oriġinarjament ingħata ‘approvazzjoni kondizzjonali'.
English: Tyverb is available as tablets (250 mg) and the recommended dose is 4 tablets a day when used with trastuzumab, 5 tablets a day when it is used with capecitabine, and 6 tablets a day when taken with an aromatase inhibitor.
Maltese: Tyverb jiġi bħala pilloli (250 mg) u d-doża rakkomandata hija 4 pilloli kuljum meta jintuża ma' trastuzumab, 5 pilloli kuljum meta jintuża ma' kapesitabina, u 6 pilloli kuljum meta jittieħed ma' inibitur tal-aromatażi.
English: Other information about Tyverb
Maltese: Informazzjoni oħra dwar Tyverb
English: Tyverb contains the active substance lapatinib.
Maltese: Tyverb fih is-sustanza attiva lapatinib.
English: The active substance in Tyverb, lapatinib, belongs to a group of medicines called protein kinase inhibitors.
Maltese: Is-sustanza attiva f'Tyverb, lapatinib, tappartjeni għal grupp ta' mediċini msejħa inibituri tal-proteina kinażi.
English: Tyverb received a conditional marketing authorisation valid throughout the EU on 10 June 2008.
Maltese: Tyverb irċieva awtorizzazzjoni kondizzjonali għat-tqegħid fis-suq valida fl-EU fl-10 ta' Ġunju 2008.
English: This was switched to a full marketing authorisation on 17 February 2015.
Maltese: Din inqalbet għal awtorizzazzjoni għat-tqegħid fis-suq sħiħa fis-17 ta' Frar 2015.
English: • in combination with trastuzumab for metastatic cancer that does not respond to hormones (hormone receptor-negative disease), and which got worse when previously treated with a combination of trastuzumab and other cancer medicines (chemotherapy);
Maltese: • flimkien ma' trastuzumab għal kanċer metastatiku li ma jkunx irrisponda għal ormoni (marda negattiva għar-riċetturi tal-ormon - ‘hormone receptor-negative disease'), u li marret għall-agħar meta fil-passat kienet ikkurata b'kombinazzjoni ta' trastuzumab u medicini oħra kontra l-kanċer (kimoterapija);
English: Palmar-plantar erythrodysaesthesia (rash and numbness on the palms and soles) is also very common when Tyverb is taken with capecitabine.
Maltese: Eritrodisestesija palmari-plantari (raxx u tnemnim fil-pali tal-idejn u fil-qiegħ tassaqajn) hija wkoll komuni ħafna meta Tyverb jittieħed ma' kapesitabina.
English: As the company has supplied the additional information necessary, the authorisation has been switched from conditional to full approval.
Maltese: Peress li l-kumpanija forniet l-informazzjoni addizzjonali meħtieġa, l-awtorizzazzjoni ma baqgħetx kondizzjonali u saret sħiħa.
English: About a quarter of breast cancers produce HER2.
Maltese: Madwar kwart tal-kanċers tas-sider jipproduċu HER2.
English: As for all medicines, data on the use of Tyverb are continuously monitored.
Maltese: Bħal għall-mediċini kollha, id-data dwar l-użu ta' Tyverb hija ssorveljata kontinwament.
English: What are the risks associated with Tyverb?
Maltese: X'inhuma r-riskji assoċjati ma' Tyverb?
English: For the full list of side effects and restrictions with Tyverb, see the package leaflet.
Maltese: Għal-lista sħiħa tal-effetti sekondarji u restrizzjonijiet rrappurtati bi Tyverb, ara l-fuljett ta' tagħrif.
English: It involved 1,286 women who had been through the menopause with metastatic breast cancer that was sensitive to hormones.
Maltese: Dan involva 1,286 mara li kienu għaddew mill-menopawża bil-kanċer metastatiku tas-sider li kien sensittiv għall-ormoni. 219-il mara kellhom kanċer li kien qiegħed jipproduċi kwantitajiet kbar ta' HER2.
English: The third study compared Tyverb with placebo (a dummy treatment), both of which were taken together with letrozole (an aromatase inhibitor).
Maltese: It-tielet studju qabbel Tyverb mal-plaċebo (kura finta), it-tnejn li huma ttieħdu flimkien ma' letrozole (inibitur tal-aromatażi).
English: Women taking Tyverb with capecitabine survived for an average of 75 weeks, and those taking capecitabine alone survived for an average of 64.7 weeks.
Maltese: In-nisa li kienu qegħdin jieħdu Tyverb flimkien ma' kapesitabina ssopravivew għal medja ta' 75 ġimgħa, u dawk li kienu qegħdin jieħdu kapesitabina waħdu ssopravivew għal medja ta' 64.7 ġimgħat.
English: • in combination with capecitabine (another cancer medicine) when the cancer is advanced or metastatic and got worse following previous treatment including an anthracycline and a taxane (other types of cancer medicine), and following treatment of the patient's metastatic disease with trastuzumab (another cancer medicine).
Maltese: • flimkien ma' kapesitabina (mediċina oħra kontra l-kanċer) meta l-kanċer ikun avvanzat jew metastatiku u jkun mar għall-agħar wara kura preċedenti li kienet tinkludi antraċiklina u tassani (tipi oħra ta' mediċina kontra l-kanċer), u wara kura tal-marda metastatika tal-pazjent bi trastuzumab (mediċina oħra kontra l-kanċer). “Avvanzat” tfisser li l-kanċer beda jinfirex u “metastatiku” tfisser li lkanċer diġà nfirex f'partijiet oħra tal-ġisem;
English: It involved 296 women with metastatic disease that was producing large quantities of HER2 and got worse despite treatment with trastuzumab and other cancer medicines (including anthracyclines and taxanes).
Maltese: Dan involva 296 mara b'marda metastatika li kienet qiegħda tipproduċi kwantitajiet kbar ta' HER2 u li marret għallagħar minkejja kura bi trastuzumab u mediċini oħrajn kontra l-kanċer (inkluż antraċiklini u tassani).
English: • in combination with an aromatase inhibitor (another type of cancer medicine) in women who have been through the menopause, when the cancer is metastatic and responds to hormones.
Maltese: • flimkien ma' inibitur aromatażi (tip ta' mediċina oħra kontra l-kanċer) f'nisa li jkunu għaddew millmenopawża, meta l-kanċer ikun metastatiku u jirrispondi għall-ormoni.
English: It involved 408 women with advanced or metastatic disease that was producing large quantities of HER2 who had already been treated with anthracyclines, taxanes and trastuzumab but whose disease had got worse or come back.
Maltese: Dan involva 408 nisa bil-marda avvanzata jew metastatika li kienet qiegħda tipproduċi kwantitajiet kbar ta' HER2 li kienu diġà ġew ikkurati bl-antraċiklini, it-tassani u trastuzumab iżda li l-marda tagħhom marret għallagħar jew reġgħet feġġet.
English: What measures are being taken to ensure the safe and effective use of Tyverb?
Maltese: X'miżuri qegħdin jittieħdu biex jiġi żgurat l-użu sigur u effettiv ta' Tyverb?
English: Side effects reported with Tyverb are carefully evaluated and any necessary action taken to protect patients.
Maltese: L-effetti sekondarji rrappurtati bi Tyverb huma evalwati bir-reqqa u kull azzjoni meħtieġa hi meħuda biex tipproteġi lill-pazjenti.
English: The most common side effects with Tyverb (which may affect more than 1 in 4 patients) are rash and side effects affecting the stomach and gut (such as diarrhoea, nausea (feeling sick) and vomiting).
Maltese: L-effetti sekondarji l-aktar komuni b'Tyverb (li jistgħu jaffettwaw aktar minn 1 minn kull 4 pazjenti) huma raxx u effetti sekondarji li jaffettwaw l-istonku u l-imsaren (bħal dijarea, nawsja (tħossok ma tiflaħx) u rimettar).
English: The women taking Tyverb in combination with capecitabine lived for an average of 23.9 weeks without their disease getting worse, as assessed by their doctors, compared with 18.3 weeks in the women taking capecitabine alone.
Maltese: In-nisa li kienu qegħdin jieħdu Tyverb flimkien ma' kapesitabina għexu għal medja ta' 23.9 ġimgħat mingħajr ma l-marda tagħhom marret għall-agħar, kif ivvalutati mit-tobba tagħhom, meta mqabbla ma' 18.3 ġimgħat fin-nisa li kienu qegħdin jieħdu kapesitabina waħdu.
English: These medicines work by blocking enzymes known as protein kinases, which can be found in some receptors (targets) on the surface of cancer cells including HER2.
Maltese: Dawn il-mediċini jaħdmu billi jimblukkaw enzimi magħrufa bħala proteini kinażi, li jinsabu f'xi riċetturi (miri) fil-wiċċ taċ-ċelloli tal-kanċer inkluż l-HER2.
English: The company that markets Tyverb will evaluate ways to predict resistance (the medicine becoming less effective) in breast cancer patients taking Tyverb with other cancer medicines.
Maltese: Tyverb jista' jinkiseb biss b'riċetta ta' tabib u għandu jinbeda biss minn tabib li jkollu esperjenza flgħoti ta' mediċini kontra l-kanċer.
English: How does Tyverb work?
Maltese: Kif jaħdem Tyverb?
English: By blocking HER2 receptors, Tyverb helps to control growth of the cancer.
Maltese: Billi jimblokka rriċetturi HER2, Tyverb jgħin biex jikkontrolla t-tkabbir tal-kanċer.
English: HER2 is a receptor for a substance called epidermal growth factor which stimulates the cancer cells to grow uncontrollably.
Maltese: L-HER2 hija riċettur għal sustanza msejħa fattur tat-tkabbir epidermali li jistimula ċ-ċelloli tal-kanċer biex jikbru bla kontroll.
English: Tyverb in combination with other cancer medicines has been shown to improve survival of patients with breast cancer that produces large quantities of HER2, and its side effects are considered acceptable.
Maltese: Tyverb flimkien ma' mediċini oħra kontra l-kanċer intwera li jtejjeb is-sopravivenza ta' pazjenti b'kanċer tas-sider li jipproduċi kwantitajiet kbar ta' HER2, u l-effetti sekondarji tiegħu jitqiesu bħala aċċettabbli.